Financial Performance - The company's revenue for Q3 2023 was ¥91,277,692.24, a decrease of 27.34% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥10,808,070.44, down 70.89% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥5,085,045.56, reflecting an 86.89% decline compared to the previous year[5]. - The basic earnings per share for Q3 2023 was ¥0.1179, a decrease of 70.90% year-on-year[5]. - Total operating revenue for Q3 2023 was CNY 388.63 million, a decrease of 2.7% compared to CNY 397.98 million in Q3 2022[19]. - Net profit for Q3 2023 was CNY 107.15 million, down 15.7% from CNY 127.13 million in Q3 2022[20]. - Basic and diluted earnings per share decreased to CNY 1.1689 from CNY 1.5130 year-over-year[21]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥78,133,591.92, down 16.21% compared to the same period last year[11]. - Cash inflow from operating activities was CNY 408.80 million, slightly down from CNY 425.42 million in the same period last year[22]. - Net cash generated from operating activities was CNY 78,133,591.92, compared to CNY 93,254,757.26 in the prior period, indicating a decrease of approximately 16.2%[23]. - Cash outflow from operating activities totaled CNY 330,662,842.13, slightly down from CNY 332,163,215.90 in the previous period[23]. - The company's cash flow from other operating activities was CNY 31,050,419.29, down from CNY 35,808,390.76, indicating a decrease of about 13.1%[23]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥2,113,709,354.06, representing a 0.73% increase from the end of the previous year[5]. - The total assets of the company as of September 30, 2023, are ¥2,113,709,354.06, compared to ¥2,098,360,763.12 at the beginning of the year[17]. - The company's inventory as of September 30, 2023, is ¥156,291,979.52, up from ¥122,688,096.16 at the beginning of the year[17]. - The total liabilities include accounts payable of ¥45,840,994.61, decreased from ¥75,900,471.01 at the beginning of the year[17]. - The company's total liabilities decreased to CNY 173.12 million from CNY 211.75 million year-over-year[20]. - The total equity attributable to shareholders increased to CNY 1,940.59 million from CNY 1,886.61 million[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,714[13]. - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of shares, totaling 55,200,000 shares[13]. - The total number of restricted shares at the end of the reporting period is 58,507,500, with 3,058,000 shares released from restriction during the period[15]. Investment Activities - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥87,121,194.00, a 3953.52% rise compared to the previous year[11]. - The company reported a 105.77% increase in net cash flow from investing activities, mainly due to the purchase of cash management products[11]. - Cash inflow from investment activities reached CNY 3,222,880,373.80, significantly up from CNY 1,024,280,109.91 in the previous period, marking an increase of about 214.5%[23]. - Net cash flow from investment activities was CNY 61,360,918.18, a turnaround from a negative CNY 1,063,390,566.33 in the prior period[23]. - Cash outflow for investment activities amounted to CNY 3,161,519,455.62, up from CNY 2,087,670,676.24, reflecting an increase of approximately 51.5%[23]. Expenses - Total operating costs increased to CNY 288.66 million, up 12.0% from CNY 257.68 million in the previous year[19]. - Research and development expenses were CNY 30.55 million, a decrease from CNY 31.19 million in the previous year[20]. - Financial expenses showed a significant improvement, with a net income of CNY -7.96 million compared to CNY -34.79 million in the previous year[20]. - Total cash outflow for employee compensation increased to CNY 64,005,702.44 from CNY 51,857,462.44, representing an increase of approximately 23.4%[23].

证券代码：301258 证券简称：富士莱 公告编号：2023-052 苏州富士莱医药股份有限公司 关于对外投资设立全资子公司 并完成工商登记的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、对外投资概述 （一）基本情况 苏州富士莱医药股份有限公司（以下简称"公司"）基于业务规划和经营发 展的需要，决定使用 25,000 万元在山东省枣庄市投资设立全资子公司富士莱（山 东）制药有限责任公司。公司本次设立全资子公司，有利于完善公司产业布局， 寻求业务拓展机会。 （二）审议情况 根据《深圳证券交易所创业板股票上市规则（2023 年修订）》和《公司章程》 等相关规定，本次对外投资事项在公司总经理权限范围之内，无需提交公司董事 会或股东大会审议。 （三）不构成关联交易 本次对外投资不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组情况。 二、设立全资子公司的基本情况 近日，全资子公司富士莱（山东）制药有限责任公司完成了工商登记手续， 并取得了峄城区行政审批服务局核发的《营业执照》，登记的相关信息如下： 1、设立子公司名称：富士莱（山东） ...

证券代码：301258 证券简称：富士莱 公告编号：2023-051 苏州富士莱医药股份有限公司 关于全资子公司对外投资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、对外投资概述 苏州贝格致远投资管理有限公司（以下简称"贝格资本"）是由苏州富士莱 医药股份有限公司（以下简称"公司"）设立的全资子公司。 2023 年 9 月 21 日，贝格资本于北京市与神济昌华（北京）生物科技有限公 司（以下简称"神济昌华"或"标的公司"）及各投资方签署了《神济昌华（北 京）生物科技有限公司之 Pre-A 轮增资协议》（以下简称"增资协议"），贝格 资本以自有资金通过货币方式对神济昌华增资 2,000 万元，增资完成后贝格资本 持有神济昌华 5.9702%股权。截至本公告披露之日，贝格资本已完成出资义务， 但工商变更登记尚未完成。 根据《深圳证券交易所创业板股票上市规则（2023 年修订）》和《公司章程》 等相关规定，本次对外投资事项无需提交公司董事会或股东大会审议，不涉及关 联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 二、交易对手方介绍 ...

证券代码：301258 证券简称：富士莱 公告编号：2023-050 苏州富士莱医药股份有限公司 关于部分首次公开发行前已发行股份上市流通的 提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 特别提示： 2022 年 9 月 29 日，公司首次公开发行网下配售限售股上市流通，数量为 1,184,117 股，占公司发行后总股本的 1.2917%，具体情况见公司 2022 年 9 月 27 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于首次公开发行网下配售限 售股上市流通的提示性公告》（公告编号：2022-050）。 2023 年 3 月 29 日，公司部分首次公开发行前已发行限售股上市流通，数量 为 10,330,000 股，占公司发行后总股本的 11.2687%，具体情况见公司 2023 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于部分首次公开发行 前已发行股份上市流通的提示性公告》（公告编号：2023-014）。 本次上市流通的限售股属于公司首次公开发行前已发行限售股，股份数量为 3,058 ...

东方证券承销保荐有限公司 关于苏州富士莱医药股份有限公司 首次公开发行前部分已发行股份上市流通的核查意见 巨潮资讯网（www.cninfo.com.cn）上披露的《关于部分首次公开发行前已发行股 份上市流通的提示性公告》（公告编号：2023-014）。 东方证券承销保荐有限公司（以下简称"东方投行"或"保荐机构"）作为 苏州富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行 股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深 圳证券交易所创业板股票上市规则（2023年修订）》、《深圳证券交易所上市公 司自律监管指引第 2号——创业板上市公司规范运作》、《深圳证券交易所上市 公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱本 次首次公开发行前部分已发行股份上市流通的事项进行了审慎核查，具体情况如 下： 一、公司首次公开发行股票的情况 本次上市流通的限售股属于公司首次公开发行前已发行的限售股，股份数量 为3,058,000股，占发行后总股本的3.34%，限售期为自公司首次公开发行并上市 之日起18个月，该部分限售股将于2023年10月9日锁定期届满并上 ...

证券代码：301258 证券简称：富士莱 公告编号：2023-049 苏州富士莱医药股份有限公司 | 股东名称 | 减持方式 | 减持时间 | 减持均价（元/股） | 减持股数（股） | 减持比例 | | --- | --- | --- | --- | --- | --- | | 钱怡 | 集中竞价交易 | 2023-6-1 | 40.68 | 2,000 | 0.0022% | | | 集中竞价交易 | 2023-7-11 | 39.88 | 10,000 | 0.0109% | 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持时间 | 减持均价（元/股） | 减持股数（股） | 减持比例 | | --- | --- | --- | --- | --- | --- | | | 集中竞价交易 | 2023-7-21 | 40.12 | 33,000 | 0.0360% | | | 集中竞价交易 | 2023-8-25 | 41.69 | 30,000 | 0.0327% | | | 合计 | - | - | 75,000 | 0.0818% | 关于监事股份减持计划实施完成的公告 监事钱怡保证向本公 ...

Group 1: Financial Performance - The company reported a net profit decline of 23.67% year-on-year for Q2 2023, primarily due to exchange gains and investment income impacts [3] - As of June 30, 2023, the company had total orders amounting to 88.12 million yuan, representing all product orders [4] - The total number of shareholders as of August 18, 2023, was 13,229 [3] Group 2: Stock and Market Strategy - The company is considering stock repurchase measures to boost stock prices, which have been below the issue price since listing [2] - The company plans to explore CMO/CDMO business opportunities and seek collaborations with other domestic pharmaceutical companies [5] - The company is actively looking for acquisition targets to enhance competitiveness and achieve resource integration [5] Group 3: Product and Market Development - The company has invested in a subsidiary focused on medical devices and cosmetics, indicating a strategic shift towards the medical beauty sector [4] - The company’s core products, including lipoic acid and phosphatidylcholine, remain central to revenue and profit, with plans to optimize production processes [5] - The company is facing challenges in export orders due to external demand fluctuations and is actively seeking new orders [4] Group 4: Risk Management and Future Outlook - The company acknowledges potential risks from market fluctuations and plans to adjust product pricing to maintain market share [6] - The company is committed to enhancing its R&D capabilities and exploring innovative solutions to remain competitive [6] - The company’s pricing strategy is not solely cost-plus, but considers market demand, inventory, and competitor pricing [6]

Financial Performance - The company's operating revenue for the first half of 2023 was ¥297,347,734.23, representing a 9.17% increase compared to ¥272,363,007.16 in the same period last year[19]. - The net profit attributable to shareholders was ¥96,342,410.67, up 7.05% from ¥90,000,334.06 in the previous year[19]. - The net cash flow from operating activities increased by 50.75% to ¥81,737,024.21, compared to ¥54,220,954.79 in the same period last year[19]. - Total assets at the end of the reporting period were ¥2,124,961,195.89, a 1.27% increase from ¥2,098,360,763.12 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 2.29% to ¥1,929,783,865.17 from ¥1,886,610,054.50 at the end of the previous year[19]. - Basic earnings per share decreased by 6.34% to ¥1.0510 from ¥1.1221 in the same period last year[19]. - The weighted average return on net assets was 4.98%, down 2.00% from 6.98% in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥84,608,672.92, a decrease of 1.06% from ¥85,511,621.61 in the previous year[19]. Revenue Breakdown - The main business revenue reached CNY 292.45 million, up 12.86% year-on-year, accounting for 98.35% of total revenue[30]. - The sales revenue from the lipoic acid series was CNY 242.48 million, an increase of 12.47% year-on-year[30]. - The phosphatidylcholine series revenue grew by 30.25% year-on-year, reaching CNY 19.32 million[30]. - The company's export revenue was CNY 187.76 million, while domestic sales amounted to CNY 104.70 million[30]. - The total sales revenue of key products, including granulated alpha-lipoic acid, L-carnitine, high-purity solvent-free alpha-lipoic acid, and 6,8-dichloro octanoic acid ethyl ester, reached 239.72 million yuan, accounting for 81.97% of the company's main business revenue[32]. Market and Competition - The overall pharmaceutical manufacturing industry in China saw a revenue decline of 2.9% year-on-year, with total revenue of CNY 1.25 trillion in the first half of 2023[29]. - The company is facing increased competition from Indian pharmaceutical manufacturers, which are gaining market share in the generic drug sector[29]. - The company aims to enhance its market share in the high-end alpha-lipoic acid raw material market through regulatory certifications in Europe and the U.S.[43]. - The company is actively expanding its application fields for alpha-lipoic acid and developing new markets and customers[43]. Research and Development - R&D expenses for the first half of 2023 amounted to 19.17 million yuan, a decrease of 5.90% year-on-year, representing 6.45% of operating revenue[39]. - The company has established a wholly-owned subsidiary in Suzhou to enhance its integration into the local biopharmaceutical industry cluster, with ongoing R&D projects in various therapeutic areas[38]. - The company plans to enhance its research and development capabilities by collaborating with renowned universities and research institutions[83]. Environmental Compliance - The company has implemented measures to enhance environmental protection and comply with national standards, which may increase operational costs[81]. - The company has valid pollutant discharge permits effective until May 16, 2028, allowing emissions of volatile organic compounds, particulate matter, and sulfur dioxide among others[95]. - The company has successfully completed environmental protection acceptance for multiple projects, confirming compliance with environmental standards[95]. - The company has implemented a wastewater treatment process that meets the discharge standards for various pollutants, including total organic carbon and suspended solids[96]. - The company has established waste gas, wastewater, and noise treatment facilities that meet the processing needs of major pollutants generated during production operations[101]. Shareholder Information - The total number of shares before the change was 91,670,000, with a reduction of 10,105,000 shares, resulting in 81,565,000 shares after the change[133]. - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of the shares, totaling 55,200,000 shares[138]. - The company has released 10,330,000 restricted shares during the reporting period, reducing the total restricted shares to 58,645,000[137]. Financial Management - The company reported a financial expense reduction of 65.12%, primarily due to changes in foreign exchange gains and losses[47]. - The company has a total of RMB 1,165,855,197.03 in financial assets, with a cumulative investment of RMB 2,646,550,391.19[60]. - The company has engaged in entrusted financial management, with a total of 263,600 million in various financial products, including 85,600 million in bank wealth management products[73]. Future Strategies - The company plans to focus on expanding its CMO/CDMO business and enhancing its product pipeline for key intermediates and specialty APIs[30]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its market share[176]. - The management provided optimistic guidance for the second half of 2023, anticipating continued growth in revenue and profitability[181].

证券代码：301258 证券简称：富士莱 公告编号：2023-046 苏州富士莱医药股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第四届董事会第八次会议 于 2023 年 8 月 18 日上午 10 时在公司会议室以现场与通讯表决方式召开，会议 通知于 2023 年 8 月 8 日以邮件、电话、书面等方式通知全体董事。本次会议应 到董事 7 人，实到董事 7 人。本次会议由董事长钱祥云先生召集并主持，公司监 事和高级管理人员列席了本次会议。会议的召集、召开及表决程序符合法律法规 及《公司章程》的有关规定。 一、议案审议情况 与会董事经过审议，以记名投票表决方式通过如下决议： （一）审议通过《2023 年半年度报告全文及其摘要》 董事会认为公司《2023 年半年度报告》和《2023 年半年度报告摘要》的编 制和审议程序符合法律法规、中国证监会和深圳证券交易所的要求，报告内容真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日刊登在巨潮资讯网（ww ...